Katja[a]
Neurology. 2006 Feb 28;66(4):587-9.
PCV chemotherapy for recurrent glioblastoma.
Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M.
Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Medical School, Tuebingen, Germany.
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.